Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus Infection

Youla S. Tsantrizos(Boehringer Ingelheim (Canada)), Daniel Lamarre(Boehringer Ingelheim (Germany)), Steven R. LaPlante, Gordon T. Bolger(Boehringer Ingelheim (Germany)), Pierre Bonneau(Biotechnology Research Institute), Montse Llinàs‐Brunet(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Nathalie Goudreau(Stem Cell Network), Dale R. Cameron(Boehringer Ingelheim (Germany)), George Kukolj(Boehringer Ingelheim (Germany))
Angewandte Chemie
March 26, 2003
10.1002/ange.200390319
Cited by 31

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285